Optimizing care for high-risk neuroblastoma patients treated with dinutuximab: Challenges for the multidisciplinary team
| Autor: | Stefanie Bekaert, Genevieve Laureys, Veronique Van De Velde, Tieneke Bauters |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Pharmacy Multidisciplinary team 03 medical and health sciences Neuroblastoma 0302 clinical medicine Maintenance therapy medicine Humans Pharmacology (medical) Intensive care medicine Child Patient Care Team Chemotherapy business.industry Dinutuximab Antibodies Monoclonal medicine.disease Transplantation Oncology 030220 oncology & carcinogenesis Stem cell business 030215 immunology |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(7) |
| ISSN: | 1477-092X |
| Popis: | Current treatment protocols for high-risk neuroblastoma include high-dose chemotherapy, surgery, stem cell transplantation and radiation. Recently, dinutuximab, a chimeric monoclonal antibody, specifically targeting the disialoganglioside highly expressed on neuroblastoma cells, has been licensed. Its incorporation in maintenance therapy represents a promising treatment approach. The introduction of its use was a challenge for the entire multidisciplinary team in our pediatric hematology and oncology ward just as for the pharmacy team. An overview of the key points that were observed is presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|